Literature DB >> 16158079

Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy.

S X Cavanaugh1, C D Fuller, P A Kupelian, C Reddy, P Bradshaw, B H Pollock, M Fuss.   

Abstract

The specific aim of this analysis was to evaluate the capability of a time and prostate-specific antigen (PSA) threshold model to prognosticate overall survival (OS) and disease-specific survival (DSS) based on early PSA kinetics after radiotherapy for prostate cancer by retrospective review of outcomes in 918 patients. Crossing below analyzed PSA thresholds at specific defined time points reduced disease-specific death hazard ratios to relative to the cohort above threshold. The time and PSA threshold model demonstrates the ability to prognosticate OS and DSS as early as 3 months post-radiotherapy for prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16158079     DOI: 10.1038/sj.pcan.4500831

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  4 in total

1.  Radiotherapy: PSA nadir predicts long-term mortality.

Authors:  Mark K Buyyounouski
Journal:  Nat Rev Clin Oncol       Date:  2010-04       Impact factor: 66.675

2.  Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death.

Authors:  Pino Alcantara; Alexandra Hanlon; Mark K Buyyounouski; Eric M Horwitz; Alan Pollack
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

3.  The impact of radiation therapy on the TCR Vβ chain repertoire in patients with prostate cancer.

Authors:  Maria Goulielmaki; Nikolaos Davanos; Paraskevi Kogionou; Panagiota Batsaki; Savvas Stokidis; Maria Adamaki; Eftychia Mosa; Evanthia Vasilakou; Charalambos Zambatis; Angelos D Gritzapis; Vassilios Zoumpourlis; Constantin N Baxevanis; Sotirios P Fortis
Journal:  Int J Oncol       Date:  2022-04-21       Impact factor: 5.884

4.  Treatment outcome and compliance to dose-intensified linac-based SBRT for unfavorable prostate tumors using a novel real-time organ-motion tracking.

Authors:  Raffaella Lucchini; Denis Panizza; Riccardo Ray Colciago; Veronica Vernier; Martina Camilla Daniotti; Valeria Faccenda; Stefano Arcangeli
Journal:  Radiat Oncol       Date:  2021-09-17       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.